SFEE strongly opposes the new claw-back calculation method

The Hellenic Association of Pharmaceutical Companies (SFEE) is strongly against and rejects in principle the new method for calculating the claw-back in Greece, as it is an unfair measure that “penalises” growth, hampers entrepreneurship and delivers no fiscal gains; its member companies reserve the right to exercise any legal right in this regard.

This is just another measure which, on top of the unified rebate and the 25% surcharge for new medicines, comes all of the sudden in the middle of the business year with a retroactive effect and reallocates burdens among companies under the disguise of “the principle of fairness.

If the Ministry of Health really wants transparency and a fairer allocation of the claw-back, it should: (a) calculate it based on the manufacturer selling prices, which reflect the companies’ actual earnings (the SFEE has long called for the calculation of the claw-back on the basis of the producer price instead of charging companies for the earnings of the rest of the supply chain); (b) put a cap on the claw-back and commit to reduce it by 30% for 2017, as envisaged in the Memorandum of Understanding; and (c) provide regular information about all expenditure components and disclose the detailed expenditure data underlying the calculation of the claw-back, as we have repeatedly requested both orally and in writing.